Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
77.73
+0.72 (+0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
48
49
Next >
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
February 23, 2023
Via
Benzinga
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
February 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Completes Acquisition of Tmunity
February 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
This Recession-Proof Company Has a Best-in-Class Dividend
February 22, 2023
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group.
Via
The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today
February 17, 2023
Via
Benzinga
Elliott Wave Technical Analysis: Gilead Inc.
February 16, 2023
Looking for a clear three wave move in wave (ii) to then place longs.
Via
Talk Markets
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
February 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
February 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
February 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
February 16, 2023
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer...
Via
SBWire
Cholecystitis Treatment Market Demand Trends Outlook Overview Analysis 2022-2029
February 16, 2023
Global Cholecystitis Treatment Market to Witness Huge Growth by Key Players: Boston Scientific, Dornier MedTech GmbH, Fresenius Kabi, AuroMedics Pharmaceuticals, Sanofi, SUNUET Pharmaceuticals, Hetero...
Via
SBWire
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
February 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday
February 14, 2023
Goldman Sachs boosted the price target for Kaiser Aluminum Corporation (NASDAQ: KALU) from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares...
Via
Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
February 13, 2023
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends.
Via
Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
February 13, 2023
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors.
Via
InvestorPlace
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
February 09, 2023
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030)
Via
SBWire
Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings
February 09, 2023
Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).
Via
Benzinga
2 Biotech Stocks That Could Make You Richer
February 09, 2023
Patience will pay off with these two stocks.
Via
The Motley Fool
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
February 09, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Thoughts For Thursday: Risk-off, Risk-on
February 09, 2023
The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible.
Via
Talk Markets
NeurAxis: Should You Buy This IPO?
February 08, 2023
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.
Via
Talk Markets
Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030
February 08, 2023
Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead...
Via
SBWire
Topics
Death
Exposures
Death
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
February 06, 2023
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.
Via
Talk Markets
Is Gilead Sciences a Good Stock to Buy Now?
February 06, 2023
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.
Via
The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
February 03, 2023
The major indexes continued to run despite mixed-to-weak earnings.
Via
Investor's Business Daily
Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting
February 03, 2023
Via
Benzinga
'Risk Of Overheating': 4 Experts On Hot January Jobs Report, How The Fed Will React
February 03, 2023
The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported blowout U.S. jobs market numbers from January.
Via
Benzinga
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
February 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
February 03, 2023
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...
Via
Benzinga
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.